TLX — Telix Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- AU$4.19bn
- AU$4.08bn
- AU$502.55m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 74.85 | ||
| PEG Ratio (f) | 1.05 | ||
| EPS Growth (f) | 251.55% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 28.11 | ||
| Price to Tang. Book | 106.65 | ||
| Price to Free Cashflow | 319.77 | ||
| Price to Sales | 8.33 | ||
| EV to EBITDA | 173.24 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.58% | ||
| Return on Equity | 4.55% | ||
| Operating Margin | 3.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.48 | 5.21 | 7.6 | 160.1 | 502.55 | 700.04 | 874.53 | 381.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +622.76 | +122.66 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines includes TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).
Directors
- H. Kevin McCann NEC
- Christian Behrenbruch CEO
- Doug Cubbin CFO
- Bernard Lambert CEX
- Shintaro Nishimura CEX
- Ludovic Wouters CEX
- Gabriel Liberatore COO
- Tracey Brown SVP
- Sunil Kadam SVP
- Melanie Farris CRO
- Jonathan Barlow GCN
- David Cade DIR
- Michael Didocha OTH
- Margaret Haarhoff OTH
- Colin Hayward OTH
- Michael Larcom OTH
- Oliver Buck NED
- Andreas Kluge NED
- Mark Nelson NID
- Jann Skinner NID
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 3rd, 2017
- Public Since
- November 15th, 2017
- No. of Shareholders
- 12,342
- No. of Employees
- 234
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 323,727,000
- Address
- Suite 401 55 Flemington Road, MELBOURNE, 3051
- Web
- https://telixpharma.com/
- Phone
- Auditors
- PricewaterhouseCoopers
Upcoming Events for TLX
Half Year 2024 Telix Pharmaceuticals Ltd Earnings Release
Similar to TLX
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Telix Pharmaceuticals share price?
As of Today at 19:21 UTC, shares in Telix Pharmaceuticals are trading at AU$12.93. This share price information is delayed by 15 minutes.
How has the Telix Pharmaceuticals share price performed this year?
Shares in Telix Pharmaceuticals last closed at AU$12.93 and the price had moved by +73.56% over the past 365 days. In terms of relative price strength the Telix Pharmaceuticals share price has outperformed the ASX All Ordinaries Index by +61.66% over the past year.
What are the analyst and broker recommendations for Telix Pharmaceuticals?
The overall consensus recommendation for Telix Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Telix Pharmaceuticals dividend yield?
Telix Pharmaceuticals does not currently pay a dividend.
Does Telix Pharmaceuticals pay a dividend?
Telix Pharmaceuticals does not currently pay a dividend.
When does Telix Pharmaceuticals next pay dividends?
Telix Pharmaceuticals does not currently pay a dividend.
How do I buy Telix Pharmaceuticals shares?
To buy shares in Telix Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Telix Pharmaceuticals?
As of the previous close price of AU$12.93, shares in Telix Pharmaceuticals had a market capitalisation of AU$4.19bn.
Where are Telix Pharmaceuticals shares listed?
Here are the trading details for Telix Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: TLX
What kind of share is Telix Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Telix Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Telix Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Telix Pharmaceuticals is AU$14.88. That is 15.07% above the last closing price of AU$12.93.
Analysts covering Telix Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of AU$0.13 for the next financial year.
What is the trend in the Telix Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Telix Pharmaceuticals. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +5.9%.
As of the last closing price of AU$12.93, shares in Telix Pharmaceuticals were trading +20.15% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Telix Pharmaceuticals PE Ratio?
The Telix Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 74.85. The shares last closed at AU$12.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Telix Pharmaceuticals?
Telix Pharmaceuticals' management team is headed by:
- H. Kevin McCann - NEC
- Christian Behrenbruch - CEO
- Doug Cubbin - CFO
- Bernard Lambert - CEX
- Shintaro Nishimura - CEX
- Ludovic Wouters - CEX
- Gabriel Liberatore - COO
- Tracey Brown - SVP
- Sunil Kadam - SVP
- Melanie Farris - CRO
- Jonathan Barlow - GCN
- David Cade - DIR
- Michael Didocha - OTH
- Margaret Haarhoff - OTH
- Colin Hayward - OTH
- Michael Larcom - OTH
- Oliver Buck - NED
- Andreas Kluge - NED
- Mark Nelson - NID
- Jann Skinner - NID